Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation
Author: Oberbauer, R.
Segoloni, G.
Campistol, J.
Kreis, H.
Mota, A.
Lawen, J.
Russ, G.
Grinyo, J.
Stallone, G.
Hartmann, A.
Pinto, J.
Chapman, J.
Burke, J.
Brault, Y.
Neylan, J.
Citation: Transplant International, 2005; 18(1):22-28
Publisher: Springer-Verlag
Issue Date: 2005
ISSN: 0934-0874
Statement of
Rainer Oberbauer, Giuseppe Segoloni, Josep M. Campistol, Henri Kreis, Alfredo Mota, Joseph Lawen, Graeme Russ, Josep M. Grinyó, Giovanni Stallone, Anders Hartmann, Jose R. Pinto, Jeremy Chapman, James T. Burke, Yves Brault and John F. Neylan for the Rapamune Maintenance Regimen Study Group
Abstract: We report the 48-month results of a trial testing whether withdrawal of cyclosporine (CsA) from a sirolimus (SRL)-CsA-steroid (ST) regimen would impact renal allograft survival. Eligible patients receiving SRL-CsA-ST from transplantation were randomly assigned at 3 months to remain on triple therapy (SRL-CsA-ST, n = 215) or to have CsA withdrawn and SRL trough concentrations increased (SRL-ST, n = 215). SRL-ST therapy resulted in significantly better graft survival, either when including death with a functioning graft as an event (84.2% vs. 91.5%, P = 0.024) or when censoring it (90.6% vs. 96.1%, P = 0.026). Calculated glomerular filtration rate (43.8 vs. 58.3 ml/min, P < 0.001) and mean arterial blood pressure (101.3 vs. 97.1 mmHg, P = 0.047) were also improved with SRL-ST. Differences in the incidences of biopsy-proven acute rejection after randomization (6.5% vs. 10.2%, SRL-CsA-ST versus SRL-ST, respectively) and mortality (7.9% vs. 4.7%) were not significant. SRL-CsA-ST-treated patients had significantly higher incidences of adverse events generally associated with CsA, whereas those in the SRL-ST group experienced greater frequencies of events commonly related to higher trough levels of SRL. In conclusion, early withdrawal of CsA from a SRL-CsA-ST regimen rapidly improves renal function and ultimately results in better graft survival.
Keywords: blood pressure; cyclosporine withdrawal; graft survival; renal function; sirolimus
Description: Copyright © 1999-2009 John Wiley & Sons, Inc.
RMID: 0020051303
DOI: 10.1111/j.1432-2277.2004.00052.x
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.